Vigadexa
Asset
Topical combination of moxifloxacin (antibacterial) and dexamethasone (corticosteroid anti-inflammatory).
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- NR3C1
- 2
- Indications
- 2,129
- Trials
- 1
- Developer
Indications
2Cataract
Phase 3, Completed, NCT00870103, clinicaltrials.gov, 7 Oct 2026
Ocular inflammation associated with blepharaconjunctivitis
Phase 3, Completed, NCT00576251, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials2,129
- Evidence for its targets3
- Competitors12
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.